SDGR · Schrodinger, Inc.

Current Thesis

Schrödinger’s Bunsen thesis now includes renewed interest in its drug-discovery partnerships; the next quarterly results must show that stronger software contracting is reaching reported revenue. The original commercial evidence remains the 2026-08-05 Bristol Myers Squibb agreement to deploy Bunsen, an artificial-intelligence research assistant, across its research organization.

The change since the September coverage is Tectora’s formation on 2026-09-09. Schrödinger contributed early-stage programs in exchange for equity and eligibility for milestones and royalties; Tectora secured $55 million from New Enterprise Associates and RA Capital Management. That financing belongs to Tectora and cannot be counted as Schrödinger revenue. Company announcement, 2026-09-09.

As an inference, the narrative is accelerating — the September 9 announcement added a new corporate development, Zacks covered the rally on September 16, and the September 18 adjusted close reached $29.02 after a three-month gain of 90.5%. This changes the earlier maturing assessment without establishing broader institutional participation. The case is fulfilled if the next quarterly report shows software revenue returning to year-over-year growth while maintaining or raising the annual contract-value outlook; the price and operating conditions below invalidate it.

Bullish and bearish views on Schrodinger, Inc.

The model's bull view on Schrodinger, Inc. (SDGR), in brief: Contracting outpaced recognized software revenue. The bear view: Software growth remains unconfirmed in revenue. Both cases follow in full.

Bull Case

• Contracting outpaced recognized software revenue. Annual contract value (ACV) reached $29.6 million in Q2 2026, up 27% year over year. The 2026-08-05 results set full-year ACV guidance at $218–228 million, representing 10–15% growth; these are the disclosed measures supporting the software-demand thesis (Q2 results, Form 8-K Exhibit 99.1).
• A named enterprise deployment exists. The Bristol Myers Squibb agreement announced on 2026-08-05 establishes a commercial reference for Bunsen. Contract-specific revenue was not supplied, so the agreement does not quantify incremental earnings (company announcement, 2026-08-05).
• Partner financing advances contributed programs. The 2026-09-09 Tectora announcement places Schrödinger’s contributed programs alongside external venture financing. Schrödinger’s ownership percentage and milestone amounts were not disclosed in that announcement, limiting valuation conclusions. Company announcement.

Bear Case

• Software growth remains unconfirmed in revenue. Reported software revenue fell approximately 10% year over year in Q2 2026 despite the ACV increase. The company attributed the divergence to hosted-contract revenue recognition; another revenue decline alongside weaker contracting would undermine that explanation (2026-08-05 Q2 results).
• Reported profit included investment gains. Q2 2026 net income of $6.0 million included approximately $45.9 million of equity-investment gains associated with Eli Lilly’s Ajax acquisition. That composition does not establish recurring operating profitability (2026-08-05 Q2 results, Form 8-K Exhibit 99.1).
• Price strength exceeds operating confirmation. The adjusted market series showed a 90.5% three-month gain and a 14-day relative strength index (RSI) of 78.6 on 2026-09-18. Those observations measure momentum; they do not resolve the software-revenue decline reported on August 5.

Setup & Price Structure

The 2026-09-18 adjusted close was $29.02, 4.0% below the supplied 52-week high of $30.24. The high is an observable reference for a breakout test, but the supplied record contains no moving-average level or repeated support tests from which to identify a new base.

The research invalidation reference is the market’s $20.09 close on 2026-09-04, before the Tectora announcement. A weekly close below $20.09 would erase the subsequent price advance and invalidate this continuation thesis. This is a dated reference close, not evidence of repeatedly tested support.

Zacks’ 2026-09-16 article described unusually high trading volume and attributed the rally to Tectora optimism. That attribution belongs to Zacks. Together with the September 18 RSI reading, it documents attention and momentum, but the available sample is too small to establish retail crowding; short-interest and investor-flow measurements are missing. Zacks, 2026-09-16.

Catalyst Calendar (next 30 days)

• 2026-09-23 — Bunsen product webinar. Schrödinger lists a presentation by Chief Technology Officer Pat Lorton covering automated scientific workflows. It provides a dated product-exposure event inside the September 20–October 20 window; the listing promises no financial update or customer announcement. Company event calendar.
• ~2026-11-04, est. Q3 2026 results. This remains an unconfirmed estimate from the September 5 coverage, outside the next 30 days. The report is the substantive test of whether software revenue resumes year-over-year growth and the company maintains its August 5 ACV guidance.

What Would Change Our Mind

Loss of the entire post-Tectora price advance would break the continuation case: a weekly close below $20.09, the September 4 reference close, is the observable failure condition. Separately, another year-over-year software-revenue decline in Q3 combined with full-year ACV guidance reduced below the previously guided 10% growth floor would invalidate the operating-conversion thesis.

A Q3 return to software-revenue growth with the August 5 ACV outlook maintained or raised would satisfy the published operating case, provided the price invalidation had not already occurred. The scheduled September 23 demonstration alone cannot establish that result because its announced scope is product functionality.

Correlation Notes

This is a single-company setup: the dated commercial anchors are the August 5 Bristol Myers Squibb agreement and September 9 Tectora transaction. No peer-return series or measured correlation coefficient is available, so the September 18 rally does not establish participation in a broader artificial-intelligence or biotechnology group move. The business spans software contracting and partnership economics, whose reported outcomes can diverge, as the August 5 ACV, software-revenue and investment-gain disclosures demonstrate.